Imprimis Pharmaceuticals Launches Simple Drops Combination Glaucoma Drops

Source: Imprimis Pharmaceuticals

Imprimis Pharmaceuticals announced the launch of its new patent-pending »Simple Drops preservative-free glaucoma drops at the American Society of Cataract and Refractive Surgery (ASCRS) 2017 meeting in Los Angeles. Imprimis is also holding a series of in-booth presentations at its exhibit booth #3038 during the meeting. 

Simple Drops preservative-free drops conveniently provide multiple glaucoma medications into a single bottle providing patients with a simple treatment option.  By providing multiple medications into one combination drop, Simple Drops may increase patient compliance and reduce costs. Each formulation is provided in a uniquely-designed bottle with PureFlow technology, which allows for a one-way valve system preventing the risk of contamination. Simple Drops consist of high-quality sterile FDA-approved components that are made and dispensed from Imprimis’ PCAB-accredited and FDA-inspected facilities. Ordering Simple Drops is easy through the online MaxRx Prescriber Portal today here.  

“We are excited with the opportunity to connect with our existing customers and meet new ones at this year’s ASCRS 2017, just a 2-hour drive from our home office. We believe our series of in-booth presentations will help increase traffic to our booth and generate additional interest in our existing and new ophthalmic portfolios,” Mark L. Baum, CEO of Imprimis, said in a company news release. “Attendees will also have the chance to learn about our new patent-pending preservative-free Simple Drops and other innovative ophthalmic compounded formulations at this year’s meeting. We believe our Simple Drops portfolio gives us a unique advantage in the marketplace because they have been designed to help improve compliance by reducing the number of drops patients administer daily. 

“In connection with the launch, we are introducing the Glaucoma Care Program to help patients better manage their conditions. Glaucoma represents the largest ophthalmic market we have entered to date, which is estimated to be over $2 billion annually in the U.S.  We conservatively estimate our total addressable market share to be $500 million. Initial market research, including focus groups and multiple surveys our team have conducted, has given us confidence that glaucoma may soon become our largest segment within our ophthalmology business. Following ASCRS 2017, our internal team of regional sales managers will work in concert with the dedicated team at Precision Lens, a leading seller of intraocular lens (IOLs) in the Midwest, to call on physicians whose patients may benefit from our unique ophthalmic formulations,” Mr. Baum said.

Glaucoma Care Program

Simple Drops preservative-free drops are more than just glaucoma medications. Many glaucoma patients have difficulties adhering to their treatment and one primary cause is the requirement to administer multiple daily drops with various dosing regimens. Under the Glaucoma Care Program, patients will receive coaching to help manage their conditions. They will also have immediate access to trained consultative pharmacists, resources to better understand their condition, receive a subscription to the monthly e-newsletter, Glaucoma Review, and the right tools to comply with treatment recommendations.  

Recent Content